AI Summary
This study focuses on the use of pembrolizumab in combination with adjuvant chemotherapy in patients with newly diagnosed, high-risk endometrial cancer. The research aims to evaluate the potential benefits of this treatment approach in patients without residual macroscopic disease post-surgery. Previous findings show that pembrolizumab plus chemotherapy can be beneficial for advanced endometrial cancer, especially in patients with certain genetic phenotypes. The results of this randomized, double-blind, phase 3 study could provide valuable insights into improving outcomes for patients with high-risk endometrial cancer.
Pembrolizumab plus chemotherapy provides clinically meaningful benefit as first-line therapy for advanced (locoregional extension and residual disease after surgery)/metastatic/recurrent pMMR and dMMR endometrial cancer (EC), with greater magnitude of benefit in the dMMR phenotype. We evaluated addition of pembrolizumab to adjuvant chemotherapy (with/without radiation therapy) among patients with newly-diagnosed, high-risk EC without any residual macroscopic disease following curative-intent surgery.